Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season by Meijer, Adam et al.
In Europe, the 2007–08 winter season was dominated 
by inﬂ  uenza virus A (H1N1) circulation through week 7, fol-
lowed by inﬂ  uenza B virus from week 8 onward. Oseltami-
vir-resistant inﬂ  uenza viruses A (H1N1) (ORVs) with H275Y 
mutation in the neuraminidase emerged independently of 
drug use. By country, the proportion of ORVs ranged from 
0% to 68%, with the highest proportion in Norway. The aver-
age weighted prevalence of ORVs across Europe increased 
gradually over time, from near 0 in week 40 of 2007 to 56% 
in week 19 of 2008 (mean 20%). Neuraminidase genes of 
ORVs possessing the H275Y substitution formed a homoge-
neous subgroup closely related to, but distinguishable from, 
those of oseltamivir-sensitive inﬂ  uenza viruses A (H1N1). 
Minor variants of ORVs emerged independently, indicating 
multiclonal ORVs. Overall, the clinical effect of ORVs in Eu-
rope, measured by inﬂ  uenza-like illness or acute respira-
tory infection, was unremarkable and consistent with normal 
seasonal activity.
I
nfection with inﬂ  uenza viruses A (H1N1), A (H3N2), 
or B causes substantial human illness and excess deaths 
each year (1,2). Vaccination against seasonal inﬂ  uenza is 
the key control measure used in Europe to minimize illness 
and death. Antigenic mismatch between vaccine compo-
nents and circulating viruses occurs every few years, re-
quiring reformulation of the vaccine (1). In addition, sub-
optimal immunization in patient groups for which vaccine 
is recommended provides the rationale for use of antiviral 
drugs in the prophylaxis and treatment of inﬂ  uenza. M2 ion 
channel inhibitors (M2Is), amantadine and rimantadine, 
have been available since 1964, but adverse effects, rapid 
development of resistance, and lack of activity against in-
ﬂ  uenza B have limited their usefulness (3). The introduc-
tion of neuraminidase inhibitors (NAIs), oral oseltamivir 
and inhaled zanamivir, which are active against both in-
ﬂ  uenza type A and B viruses, was a major breakthrough 
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in treatment and prophylaxis of inﬂ  uenza using antiviral 
drugs (4). However, prescription data indicate that they are 
not widely used in Europe (Figure 1); by contrast, in Japan 
during the 2003–04 season alone, ≈6 million NAI treatment 
courses were prescribed (5).
Before the introduction of NAIs in 1999, and until 
2007, <1% of viruses tested from unselected surveillance 
studies in a number of countries demonstrated natural re-
sistance to NAIs (5–9). Limited development of resistance 
to oseltamivir has been observed in persons treated, with 
little evidence of onward transmission of resistant viruses 
(10), although low-level transmission of resistant variants 
cannot be discounted (11). However, oseltamivir-resistant 
viruses emerged in 18% (9/50) of treated Japanese children 
with inﬂ  uenza virus A (H3N2) infection and 16% (7/43) of 
treated Japanese children with inﬂ  uenza virus A (H1N1) 
infection, also with no evidence that these viruses transmit-
ted efﬁ  ciently (12,13).
In late January 2008, we reported an unexpected high 
level and unexpected spread of oseltamivir-resistant in-
ﬂ  uenza viruses A (H1N1) (ORVs) in Europe caused by a 
H275Y (H274Y in N2 numbering) amino acid substitution 
in the neuraminidase (NA) of these viruses (14). Here, we 
analyze the distribution and transmission of ORVs in Eu-
rope during the winter of 2007–08, when inﬂ  uenza viruses 
A (H1N1) were the predominant circulating viruses in Eu-
ropean countries (Table).
Methods
Clinical Inﬂ  uenza Activity
The European Inﬂ  uenza Surveillance Scheme (EISS) 
actively monitored inﬂ  uenza activity from week 40 (Oc-
tober 1–7) of 2007 through week 19 (May 5–11) of 2008. 
EISS covers all 27 European Union countries plus Croa-
tia, Norway, Serbia, Switzerland, Turkey, and Ukraine. In 
each country each week, 1 or several networks of sentinel 
general practitioners (GPs) reported rates of consultation 
for inﬂ  uenza-like illness (ILI) or acute respiratory infec-
tion (ARI) (15–17). ARI includes ILI and all other acute 
respiratory infections. For Croatia, Finland, Turkey, and 
Ukraine, no consultation data were available.
Virologic Analysis
Sentinel GPs involved in clinical data recording of 
ILI or ARI also send nasal, pharyngeal, or nasopharyngeal 
specimens from a subset of their patients to the National 
Inﬂ  uenza Centers (NICs) for virus detection and character-
ization by using a variety of genetic or phenotypic methods 
(18–20). The NICs also analyzed specimens and inﬂ  uenza 
viruses obtained from other sources (e.g., from nonsentinel 
GPs, hospitals, or institutions). For Cyprus and Turkey, no 
virus detection data were available.
Antiviral Drug Susceptibility Monitoring
Antiviral susceptibility data were generated either 
through the European Surveillance Network for Vigilance 
against Viral Resistance (VIRGIL) project at a single labo-
ratory in London (UK Health Protection Agency) or direct-
ly by individual NICs by using methods described previ-
ously (14,21). Genetic analysis of virus isolates or clinical 
specimens was performed by using cycle-sequencing or 
pyrosequencing the NA gene, targeting the H275Y amino 
acid substitution in the N1 NA (22). The 50% inhibitory 
NAI concentration (IC50) of virus isolates was determined 
by using ﬂ  uorescent or chemiluminescent enzyme assays 
(23,24). ORVs were deﬁ  ned as inﬂ  uenza viruses A (H1N1) 
with an IC50 >100 nmol/L for oseltamivir. Susceptibility 
to zanamivir was determined by using the same enzymatic 
method. Susceptibility to M2Is was determined by cycle-
sequencing or pyrosequencing the M2 protein gene, target-
ing known resistance markers. Antiviral susceptibility data 
were not available for Cyprus, Lithuania, and Malta.
Data Analysis
To obtain United Kingdom estimates, clinical and vi-
rologic surveillance data and antiviral susceptibility data 
were totaled for England, Northern Ireland, Scotland, and 
Wales. A single web-based European database at the EISS 
password-protected website (www.eiss.org) was used to 
collect antiviral susceptibility data and linked patient de-
mographic and clinical data (25). Updates on possible re-
sistant viruses were provided at regular intervals to EISS 
members, the World Health Organization, and the Euro-
pean Centre for Disease Prevention and Control.
The timing of the ﬁ  rst week of continuous detection of 
inﬂ  uenza virus A and ORVs across Europe, both based on 
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Germany 4 211 100 442 128 121 71
France 0 27 49 104 24 93 50
Greece 0 45 41 30 4 2 4
Finland 0 9 2 15 3 7 2
Belgium 1 7 3 33 7 18 8
Austria 0 4 5 30 2 4 7
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Figure 1. Prescription data of oseltamivir treatment courses for 
Western Europe (in thousands); 12 months of data for each year 
2002–2007 and through September for 2008. Data from the United 
Kingdom, the Netherlands, Switzerland, and Portugal are excluded 
because of negligible values. Data provided by IMS Health (www.
imshealth.com), London, UK.RESEARCH
date of specimen collection, were analyzed by linear regres-
sion analysis using center longitude and center latitude of a 
country as explanatory variables. A maximum interruption 
of 1 week with no inﬂ  uenza virus A or ORV detection was 
allowed in estimating the ﬁ  rst week of continuous detec-
tion. The average European delay between the ﬁ  rst week of 
continuous detection of inﬂ  uenza virus A and of ORV was 
calculated as the average of the differences in number of 
weeks between both, by country.
The analysis of temporal trends in the prevalence of 
ORVs in countries and for Europe was confounded by dif-
ferent levels of sampling in different countries (18), en-
hanced antiviral susceptibility testing in some countries, 
and lack of data on the proportion of ORVs for some or 
most weeks for several other countries. To ensure a more 
representative picture of temporal trends in the proportion 
of ORVs, a mixed effect logistic regression modeling ap-
proach (26,27) was used, which allows modeling of bino-
mial proportions, i.e., a numerator and a denominator as a 
function of time, where the coefﬁ  cients of this function are 
allowed to vary for each country around a mean value, com-
bining data from all countries. If there are no observations 
or the denominator is small, the ﬁ  t will shrink to its over-
all mean, and uncertainties increase. Three fractions were 
modeled: “ILI per population covered,” “inﬂ  uenza A virus 
detections per specimens tested,” and “A (H1N1) resistant 
per A (H1N1) tested.” By multiplying the ﬁ  rst 2 fractions 
by the total population, we obtained the number of patients 
with ILI who had inﬂ  uenza A in a country. By dividing this 
number by the sum of the number of patients with ILI who 
had inﬂ  uenza A for all countries, we obtained the relative 
weights. By multiplying the weights with the prevalences 
of ORVs summed over all countries, we obtained the week-
ly European prevalences of ORVs. The modeled weekly 
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Table. Peak incidence rates of ILI or ARI infection for countries for which data were available, Europe, 2000–01 through 2007–08
influenza seasons* 
Peak incidence rate/10,000 population during influenza season 
2000–01 through 2007–08 
Peak incidence 
rates¶ 
 Dominant virus§ 
Country 
ILI/
ARI† Median Range
Consecutive
no. seasons‡  2000–01 2007–08
Incidence
rate ratio p value 
Austria# ILI 168.1 108.0–263.2 4 NA 186.1 (H1) 
Belgium ILI 51.9 30.3–95.1 8 30.3 (H1)  38.0 (H1)  1.3 0.004
Bulgaria ARI NA NA 186.0 (H1) 
Czech Republic  ARI 188.1 134.5–320.0 8 310.2 (H1)  144.4 (H1)  0.5 1.000
Denmark ILI 30.7 13.8–47.8 8 44.5 (H1)  13.8 (H1)  0.3 1.000
Estonia ILI 2.9 0.6–4.9 3 NA 2.9 (H1) 
France ARI 336.1 279.7–448.8 7 NA 279.7 (H1) 
Germany  ARI 185.6 136.9–256.5 8 247.3 (H1)  136.9 (H1/B)  0.6 1.000
Greece ILI 27.7 23.1–42.1 3 NA 23.1 (H1) 
Hungary ILI 50.1 21.0–54.6 3 NA 54.6 (H1) 
Ireland ILI 7.5 2.9–12.1 8 12.1 (H1)  4.9 (H1/B)  0.4 1.000
Italy  ILI 79.5 27.6–428.2 8 56.7 (H1)  72.1 (H1/B)  1.3 0.0001
Latvia ILI 45.6 25.1–93.3 5 NA 26.6 (H1) 
Lithuania ILI 34.9 13.3–47.2 7 NA 13.3 (H1) 
Luxembourg ILI 72.6 32.7–79.1 5 NA 67.4 (H1) 
The Netherlands  ILI 10.3 6.6–24.0 8 6.9 (H1)  7.2 (H1/B)  1.0 0.400
Norway ILI 18.5 10.9–31.7 3 NA 10.9 (H1/B) 
Poland ILI 23.0 6.2–66.7 7 NA 16.6 (H1) 
Portugal ILI 8.1 3.0–17.4 8 3.8 (H1)  6.2 (H1/B)  1.6 0.016
Romania ILI 1.2 0.4–3.7 4 NA 1.4 (H1) 
Serbia ILI 37.8 30.6–44.9 2 NA 30.6 (H1) 
Slovakia ILI 136.3 49.5–337.3 8 337.3 (H1)  49.5 (H1)  0.1 1.000
Slovenia ILI 15.2 4.5–39.2 8 14.1 (H1)  20.4 (H1)  1.5 0.001
Spain ILI 21.2 4.2–54.1 8 4.2 (H1)  20.3 (H1/B)  4.8 0.0001
Sweden#  ILI 2.0 1.6–5.8 5 5.8 (H1)  1.8 (B)  0.3 1.000
Switzerland ILI 39.8 19.4–53.2 7 NA 29.7  (H1) 
United Kingdom  ILI 3.8 2.7–8.4 8 5.5 (H1)  2.7 (H1/B)  0.5 1.000
*ILI, influenza-like illness; ARI, acute respiratory infection; NA, data not available. 
†For countries where both ILI and ARI data were available, only the ILI data are shown. 
‡Leading up to 2007–08. 
§Dominant virus estimated on the basis of combined sentinel and nonsentinel data. The limits for codominant virus types/subtypes were 45%:55%. 
¶2007–08 compared with 2000–01. The incidence rate ratio was calculated by dividing the peak incidence rate for 2007–08 by the peak incidence rate for 
2000–01. If the p value estimated using z-statistics is <0.05, the incidence rate ratio is significantly >1, and therefore the peak incidence rate for 2007–08 
is significantly higher than that for 2000–01. 
#Data for seasons 2002–03, 2003–04, and 2004–05 were missing. Oseltamivir-Resistant Inﬂ  uenza A (H1N1) Virus
prevalences of ORVs were subsequently used to calculate 
the average prevalence of ORVs by country and for Europe 
(online Technical Appendix, available from www.cdc.gov/
EID/content/15/4/552-Techapp.pdf).
We performed all statistical analyses by using the soft-
ware package R version 2.8.0 (28). Box-and-whisker plot 
analysis was used to select viruses with outlying high IC50 
values for further analysis (7,29). For oseltamivir outlier 
identiﬁ  cation, all viruses deﬁ  ned as resistant for oseltami-
vir (IC50 >100 nmol/L) were ﬁ  rst removed. Minor outliers 
were deﬁ  ned as values lying between the upper quartile 
(UQ) + 1.5 × interquartile region (IQR) and UQ + 3 × IQR; 
major outliers were deﬁ  ned as values lying above UQ + 3 × 
IQR, based on analysis of all viruses in a particular subtype 
over a particular winter season.
Phylogenetic analysis of NA and hemagglutinin (HA) 
gene sequences used maximum parsimony (PAUP* version 
4.0; Sinauer Associates, Sunderland, MA, USA). Sequences 
of ORVs and oseltamivir-sensitive inﬂ  uenza A (H1N1) vi-
ruses (OSVs) were chosen as representative of inﬂ  uenza vi-
ruses A (H1N1) isolated during the 2007–08 inﬂ  uenza sea-
son (i.e., weeks 40–52 of 2007 and weeks 1–19 of 2008) in 
different European countries and a few from other regions 
of the world and were compared with those of a few inﬂ  u-
enza viruses A (H1N1) isolated before the 2007–08 season, 
including sporadically isolated ORVs. GenBank accession 
numbers are listed in the online Appendix Table (available 
from www.cdc.gov/EID/content/15/4/552-appT.htm).
Results
Seasonal Surveillance
The 2007–08 inﬂ  uenza season in Europe was initially 
dominated by inﬂ  uenza viruses A (n = 10,720; 60% of all 
inﬂ  uenza virus detections). Inﬂ  uenza viruses B (n = 7,150; 
40% of all inﬂ  uenza virus detections) became dominant in 
week 8 (Figure 2). Of the 5,984 (56%) inﬂ  uenza viruses 
A subtyped, 5,748 (96%) were H1, and 236 (4%) were 
H3. Overall, inﬂ   uenza virus detections peaked in week 
6, in week 4 for inﬂ  uenza viruses A (H1N1), and in week 
8 for inﬂ  uenza viruses B. Of the 2,136 inﬂ  uenza viruses 
A (H1N1) characterized antigenically, 97% were report-
ed to be closely related to the vaccine strain A/Solomon 
Islands/3/2006, although half of these viruses were report-
ed to be more closely related to A/Brisbane/59/2007, the 
vaccine strain recommended for the 2008–09 season (30).
The ﬁ  rst countries in Europe where inﬂ  uenza viruses 
A started to circulate continuously were France, Spain, 
Switzerland, and the United Kingdom in week 40. Spatial 
analysis of the timing of the ﬁ  rst week of continuous detec-
tion of inﬂ  uenza viruses A across Europe (n = 30 coun-
tries) showed a west-to-east pattern: estimated parameter 
for longitude was 0.261 weeks per degree longitude (95% 
conﬁ  dence interval [CI] 0.138–0.385, p = 0.001), and for 
latitude –0.108 weeks per degree latitude (95% CI –0.324 
through 0.108, p = 0.366), with R2 = 0.32 for the linear 
regression ﬁ  t.
Antiviral Drug Susceptibility
The estimated number of inﬂ  uenza viruses A (H1N1) 
among all detected inﬂ  uenza viruses A (n = 10,720) was 
10,291 following extrapolation from the proportion of 
96% inﬂ  uenza viruses A (H1N1) among all 5,984 sub-
typed inﬂ  uenza viruses A. Of the 10,291 inﬂ  uenza vi-
ruses A (H1N1), 2,949 (29%) were tested for antiviral 
susceptibility, 1,080 by both phenotypic assay (IC50) and 
sequencing, 601 by phenotypic assay alone, and 1,268 
by sequencing alone. Of the 2,949 viruses tested, 712 
(24%) were oseltamivir resistant either by presence of the 
H275Y substitution (n = 548) or an IC50 >100 nmol/L for 
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Figure 2. Total number of inﬂ  uenza virus detections, by type and 
subtype and by week, Europe, winter 2007–08.
Figure 3. Total inﬂ  uenza A viruses subtyped as H1N1 and number 
of oseltamivir-resistant or oseltamivir-sensitive viruses among 
the subset of inﬂ   uenza viruses A (H1N1) for which oseltamivir 
susceptibility was determined, by week, Europe, winter 2007–08.RESEARCH
oseltamivir (n = 463) (Figure 3). Correlation was 100% 
between sensitive phenotype (IC50 <100 nmol/L) and the 
presence of H275 (n = 781) and between resistant phe-
notype (IC50 >100 nmol/L) and the presence of Y275 
(n = 299). OSVs (n = 1,218) had a median IC50 of 1.7 
nmol/L for oseltamivir (range 0.1 nmol/L–23.2 nmol/L) 
and only 9 minor outliers (thresholds IC50 >12.0 nmol/L 
and <53.1 nmol/L) were identiﬁ  ed. ORVs (n = 463) had 
a median IC50 of 653 nmol/L (range 140 nmol/L–4,000 
nmol/L). None of the 429 phenotypically characterized 
ORVs showed evidence of resistance to zanamivir (me-
dian IC50 1.8 nmol/L, range 0.2 nmol/L–25.8 nmol/L), and 
only 17 minor outliers (thresholds IC50 >8.5 nmol/L and 
<27.5 nmol/L) were identiﬁ  ed. None of 237 ORVs tested 
for M2I sensitivity had any of the common resistance sub-
stitutions in the M2 protein.
ORVs were detected in 22 of the 30 countries for which 
susceptibility data were available, with Norway having the 
highest proportion of ORVs (Figure 4). Modeling showed 
the overall average prevalence of ORVs by country ranged 
from 8.3% (95% CI 1.3%–21%) in Italy to 65.0% (95% CI 
58.2%–71.3%) in Norway; for Europe, the average preva-
lence of ORVs was 20.1% (95% CI 15.2%–24.6%).
The earliest detection of ORVs was in France and the 
United Kingdom in week 46 and in Norway in week 47. 
Countries where continuous detection of ORVs ﬁ  rst be-
gan included Norway in week 47, France in week 49, the 
United Kingdom in week 51, and the Netherlands in week 
52. Spatial analysis of the timing of the ﬁ  rst week of con-
tinuous ORV detection across Europe (n = 14 countries) 
showed a west-to-east trend pattern: estimated parameter 
for longitude was 0.156 weeks per degree longitude (95% 
CI 0.033–0.280, p = 0.031), and for latitude 0.007 weeks 
per degree latitude (95% CI –0.209 through 0.223, p = 
0.953), with R2 = 0.36 for the linear regression ﬁ  t. The av-
erage delay between the ﬁ  rst week of continuous detection 
of inﬂ  uenza virus A and continuous detection of ORV was 
5.7 weeks (range 0–15, 95% CI 2.8–8.4).
Modeling showed a gradual increase for Europe in 
prevalence of ORVs over time, from close to 0 in week 40 
to ≈56% in week 19 (Figure 5). This overall increase re-
ﬂ  ected prevalence increases in most individual countries in 
addition to Norway where the modeled prevalence started 
high at ≈60% and remained so throughout the period of 
virus circulation (online Appendix Figure, available from 
www.cdc.gov/EID/content/15/4/552-appF.htm). Outside 
the main inﬂ  uenza virus A (H1N1) outbreak period, from 
week 51 to week 10 (Figure 2), the CIs for the prevalence 
of ORVs by country and for Europe were wide (Figure 5; 
online Appendix Figure) because of the low numbers of 
inﬂ  uenza virus A (H1N1) detected or analyzed for antiviral 
resistance (online Technical Appendix).
Phylogenetic Analysis
Phylogenetic comparisons of HA and NA genes 
showed that the sequences of most recent European inﬂ  u-
enza viruses A (H1N1) fell within clade 2B, represented by 
A/Brisbane/59/2007, the recently recommended vaccine 
virus for 2008–09 (Figure 6). The NA sequences of most 
European ORVs form a cluster, characterized by a differ-
ence in amino acid residue 354 (D354G), as well as 275 
(H275Y) compared with OSVs, including some ORVs from 
the United States and Japan (30,31). A degree of heteroge-
neity was observed, especially among ORVs from the Unit-
ed Kingdom; however, the NA sequences in these smaller 
clusters, represented by, for example, A/Scotland/5/2008 
(and A/Hawaii/21/2007) or A/England/654/2007, are not 
distinguished from those of OSVs by any common amino 
acid differences other than H275Y. Some of these sequenc-
es fall close to those of ORVs recently isolated in Japan 
(31). The corresponding HA gene sequences within clade 
2B, however, did not exhibit segregation complementary 
to that for NA gene sequences and no common amino 
acid changes distinguished ORVs and OSVs (Figure 6). 
Although the D344N substitution in NA has been associ-
ated with increases in the enzyme activity (32), this amino 
acid is common to both clades 2B and 2C, and none of the 
clade-speciﬁ  c differences between the NA (13 amino acids) 
or HA (6 amino acids) can readily account for the greater 
proportion of ORVs in clade 2B over clade 2C viruses.
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Prevalence of oseltamivir-resistant influenza viruses A (H1N1)
Italy
Czech Republic
Serbia
Spain
Austria
Latvia
Slovakia
Hungary
Denmark
Bulgaria
Slovenia
Romania
Croatia
Germany
Sweden
Poland
Turkey
Greece
Ireland
Portugal
United Kingdom
Netherlands
Luxembourg
Switzerland
Finland
Estonia
Ukraine
Belgium
France
Norway
Europe
No. resistant No. tested
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Figure 4. Modeled average prevalence of oseltamivir-resistant 
inﬂ  uenza viruses A (H1N1), with 95% conﬁ  dence intervals (error 
bars), ranked by country, Europe, winter 2007–08. Text columns on 
the right list the absolute cumulative number of oseltamivir-resistant 
inﬂ   uenza viruses A (H1N1) and number of inﬂ  uenza  viruses  A 
(H1N1) tested for oseltamivir susceptibility per country.Oseltamivir-Resistant Inﬂ  uenza A (H1N1) Virus
Discussion
Unexpectedly, inﬂ  uenza viruses A (H1N1) with a sin-
gle amino acid substitution H275Y in the NA, which caused 
a several hundred-fold selective reduction in susceptibility 
to oseltamivir, emerged and were sustained in circulation 
in Europe during 2007–08, despite low antivirual drug use 
(Figure 1). Before the 2007–08 season, <1% of viruses 
tested since the start of European antiviral surveillance 
in 2004 had IC50 values >100 nmol/L for NAI drugs (A. 
Lackenby et al., unpub. data), in concordance with results 
from worldwide surveillance (8,9). In 2007–08, inﬂ  uenza 
viruses A (H3N2) and B circulating in Europe remained 
sensitive to NAI drugs.
This emergence of oseltamivir-resistant inﬂ  uenza vi-
rus A (H1N1) in Europe coincided with the dominant cir-
culation of this virus subtype during the 2007–08 winter 
in Europe and the emergence of a new drift variant, A/
Brisbane/59/2007 (30). Of the last 12 inﬂ  uenza seasons, in-
ﬂ  uenza viruses A (H1N1) were dominant only in 2000–01, 
which included a new drift variant, A/New Caledonia/20/99 
(20). In the other 10 seasons, inﬂ  uenza viruses A (H1N1) 
played a minor role, with inﬂ  uenza viruses A (H3N2) domi-
nant in 9 seasons. Compared with 2000–01, peak incidence 
rates for ILI or ARI in 7 of 13 countries were similar or 
lower in 2007–08 (Table). In 6 countries, the peak inci-
dence rates were signiﬁ  cantly higher in 2007–08 than in 
2000–01, but with a <2-fold difference in 5 countries and, 
in Spain only, a 4.8-fold difference. Both the 2000–01 and 
2007–08 seasons were unremarkable in the overall clinical 
impact of inﬂ  uenza, with normal seasonal activity as mea-
sured by comparison of peak incidence rates for all seasons 
since 2000–01.
Sporadically occurring A/New Caledonia/20/99-like 
ORVs with H275Y were detected during the 2006–07 sea-
son in the United Kingdom and United States but did not 
become epidemiologically important. Indeed, the genetic 
background plays a role in retaining the replication efﬁ  -
ciency and pathogenicity of recombinant inﬂ  uenza viruses 
A (H5N1) and A (H1N1) after introduction of tyrosine at 
position 275 (33). Furthermore, other previously analyzed 
inﬂ   uenza viruses A (H1N1) with the H275Y mutation 
showed impaired replicative ability in cell culture and re-
duced infectivity and substantially compromised pathoge-
nicity in animal models, compared with the corresponding 
wild-type virus (34,35). The coincidental emergence of 
H275Y with the circulation of the A/Brisbane/59/2007 drift 
variant may have favored the emergence of ﬁ  t transmissible 
ORVs. This point is also illustrated by the emergence of A/
Brisbane/59/2007-like ORVs in other parts of the Northern 
Hemisphere and their continued circulation during the 2008 
Southern Hemisphere inﬂ  uenza epidemic season (36–38). 
Since the last quarter of 2007, ORVs have been detected 
in continents other than Europe, with proportions of ORVs 
varying from 100% in South Africa and Australia to <5% 
in Japan. Trend data are limited: a slight monthly increase 
was noted in China/Hong Kong and Japan; in Canada, the 
increase was similar to that in Europe, from 0% ORVs in 
November 2007 to 86% ORVs in April 2008 (36).
Using modeling, we showed that the prevalence of 
ORVs increased in the European region from ≈0% at the 
start to 56% at the end of the season. The ﬁ  nding of a high 
prevalence of ORVs in the community and the overall tem-
poral increase in resistance demonstrates that the previously 
documented reduced ﬁ  tness of viruses bearing the H275Y 
mutation, ostensibly caused by structural and functional 
constraints (10), has been overcome in currently circulating 
inﬂ  uenza viruses A (H1N1). The results of Rameix-Welti 
et al. (32) suggest that a combination of speciﬁ  c amino acid 
substitutions have increased the afﬁ  nity of the NA of recent 
inﬂ  uenza viruses A (H1N1) (ORVs and OSVs) for sub-
strate. A better balance of NA and HA activities in ORVs 
compared with OSVs may have contributed to the over-
all ﬁ  tness and transmissibility of ORVs. However, growth 
curves conducted in tissue culture of pairs of ORVs and 
OSVs demonstrated no differences in growth kinetics or ﬁ  -
nal virus yields. Therefore, changes in other genes also may 
be involved in the overall impact on the ﬁ  tness of ORVs, 
for which whole genome sequencing is necessary.
For Europe, no focal point of initiation of spread could 
be identiﬁ  ed. The spread of ORV from west to east paral-
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Figure 5. Weighted average prevalence of oseltamvir-resistant 
inﬂ  uenza viruses A (H1N1), Europe, winter 2007–08. The light gray 
region indicates the 95% conﬁ  dence interval.RESEARCH
leled that of inﬂ  uenza virus A in Europe, and there was an 
average delay of 5.7 weeks for the appearance of ORVs 
after the start of inﬂ  uenza virus A circulation. However, the 
low R2 values for both patterns make deﬁ  nitive conclusions 
difﬁ  cult to draw about the spatial spread of either inﬂ  uen-
za viruses A or ORVs. Several independent introductions 
into European countries of a sensitive and a resistant strain 
might explain the low R2 values.
Estimating whether a global focal point exists from 
which ORVs emerged to spread to the rest of the world is 
not possible, but the fact that Japan, the country with the 
highest per capita use of oseltamivir (5), had relatively low 
levels of circulating ORVs during the 2007–08 inﬂ  uenza 
season is relevant and reﬂ  ects the limited circulation of the 
clade 2B A/Brisbane/59/2007-like viruses belonging to the 
European cluster in this region (31,36).
The close relationships between the NA sequences 
of most of the 2007–08 European ORVs and their segre-
gation from those of OSVs suggest that resistance results 
in large part from the spread of a single variant. Phyloge-
netic analyses show that this is a property of clade 2B A/
Brisbane/59/2007-like viruses and is not associated with 
emergence of another antigenic variant. However, identi-
ﬁ  cation of other resistant variants in the United Kingdom, 
some of which are more closely related to OSVs than to 
most ORVs (e.g., A/England/654/2007) indicates the inde-
pendent parallel emergence of multiple resistant variants. 
This is emphasized by small distinct clusters of closely re-
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Figure 6. Phylogenetic comparisons of the hemagglutinin (A) and neuraminidase (B) genes of inﬂ  uenza viruses A (H1N1). Sequences 
of oseltamivir-resistant viruses, possessing the H275Y (H274Y in N2 numbering) mutation are in boldface; vaccine strains are in italics. 
Common amino acid changes that distinguish clades 1 and 2 and subgroups of clade 2 are shown. Scale bars indicate 0.01 nucleotide 
substitutions per site.Oseltamivir-Resistant Inﬂ  uenza A (H1N1) Virus
lated ORVs in Japan that are related to European OSVs, 
whereas only a few of the Japanese ORVs belonged to the 
large European ORVs cluster (31). Resolution of the origin 
and frequency of emergence of ORVs and association with 
drug use clearly require substantially more intimate knowl-
edge of the genetic relationships among OSVs and ORVs 
worldwide. Our observations suggest that the new genetic 
background of inﬂ  uenza viruses A (H1N1) that appeared 
in 2007 enabled the virus to develop oseltamivir resistance 
independently at several locations in the world.
The combined effect of the relatively high level of cir-
culation of inﬂ  uenza viruses A (H1N1) in Europe; the in-
troduction of a new antigenic drift variant in a susceptible 
population, partly related to the lack of substantial inﬂ  u-
enza virus A (H1N1) circulation since the 2000–01 season; 
and the uncompromised transmissibility of the ORVs con-
tributed to the epidemiologic success of the ORVs during 
the 2007–08 season. This phenomenon shows clearly that 
continuation of antiviral susceptibility monitoring and in-
creasing capacity for timely response are essential (21,39). 
In addition, the appearance of viable transmitting ORVs is 
a reminder that the level of resistance to oseltamivir of sea-
sonal or pandemic virus cannot be predicted, and therefore 
antiviral strategies should not rely on single drugs (40). Al-
though oseltamivir remains a valuable inﬂ  uenza antiviral 
agent, the emergence of natural resistance shifts attention 
from oseltamivir to other antiviral agents and to improved 
vaccination (e.g., greater vaccination coverage, more im-
munogenic and broadly reacting vaccines) in the ﬁ  ght 
against seasonal and pandemic inﬂ  uenza.
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